MiR-378a-5p Regulates Proliferation and Migration in Vascular Smooth Muscle Cell by Targeting CDK1

被引:39
作者
Liu, Shaoyan [1 ]
Yang, Yanyan [2 ]
Jiang, Shaoyan [3 ]
Xu, Hong [4 ]
Tang, Ningning [2 ]
Lobo, Amara [1 ]
Zhang, Rui [1 ]
Liu, Song [1 ]
Yu, Tao [2 ]
Xin, Hui [1 ]
机构
[1] Qingdao Univ, Affiliated Hosp, Dept Cardiol, Qingdao, Peoples R China
[2] Qingdao Univ, Inst Translat Med, Qingdao, Peoples R China
[3] Qingdao Univ, Affiliated Hosp, Dept Cardiol, Qingdao, Peoples R China
[4] Qingdao Univ, Affiliated Hosp, Dept Orthodont, Qingdao, Peoples R China
基金
中国博士后科学基金; 中国国家自然科学基金;
关键词
miR-378a-5p; vascular smooth muscle cell; stent-restenosis; proliferation; migration; atherosclerosis; CDK1; IN-STENT RESTENOSIS; ELUTING STENT; MICRORNA-378A-5P; EXPRESSION; THROMBOSIS; CANCER; CYCLE;
D O I
10.3389/fgene.2019.00022
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Objective: Abnormal proliferation or migration of vascular smooth muscle cells (VSMCs) can lead to vessel lesions, resulting in atherosclerosis and in stent-restenosis (IRS). The purpose of our study was to establish the role of miR-378a-5p and its targets in regulating VSMCs function and IRS. Methods: EdU assays and Cell Counting Kit-8 (CCK-8) assays were applied to evaluate VSMCs proliferation, wound healing assays and transwell assays were applied to assess cells migration. Furthermore, quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was performed to investigate the expression level of miR-378a-5p IRS patients and healthy individuals. Target genes were predicted using Target Scan and miRanda software, and biological functions of candidate genes were explored through bioinformatics analysis. Moreover, RNA-binding protein immunoprecipitation (RIP) was carried out to analyze the miRNAs interactions with proteins. We also used lmmunofluorescence (IF) and fluorescence microscopy to determine the binding properties, localization and expression of miR-378a-5p with downstream target CDK1. Results: The expression of miR-378a-5p was increased in the group with stent restenosis compared with healthy people, as well as in the group which VSMCs stimulated by platelet-derived growth factor-BB (PDGF-BB) compared with NCs. MiR-378a-5p over-expression had significantly promoted proliferative and migratory effects, while miR-378a-5p inhibitor suppressed VSMC proliferation and migration. CDK1 was proved to be the functional target of miR-378a-5p in VSMCs. Encouragingly, the expression of miR-378a-5p was increased in patients with stent restenosis compared with healthy people, as well as in PDGF-BB-stimulated VSMCs compared with control cells. Furthermore, co-transfection experiments demonstrated that miR-378a-5p overexpression promoted proliferation and migration of VSMCs specifically by reducing CDK1 gene expression levels. Conclusion: In this investigatory, we concluded that miR-378a-5p is a critical mediator in regulating VSMC proliferation and migration by targeting CDK1/p21 signaling pathway. Thereby, interventions aimed at miR-378a-5p may be of therapeutic application in the prevention and treatment of stent restenosis.
引用
收藏
页数:10
相关论文
共 33 条
[1]   NCK Associated Protein 1 Modulated by miRNA-214 Determines Vascular Smooth Muscle Cell Migration, Proliferation, and Neointima Hyperplasia [J].
Afzal, Tayyab Adeel ;
Le Anh Luong ;
Chen, Dan ;
Zhang, Cheng ;
Yang, Feng ;
Chen, Qishan ;
An, Weiwei ;
Wilkes, Edmund ;
Yashiro, Kenta ;
Cutillas, Pedro R. ;
Zhang, Li ;
Xiao, Qingzhong .
JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2016, 5 (12)
[2]   A randomized comparison of sirolimus-eluting stent with balloon angioplasty in patients with in-stent restenosis -: Results of the restenosis intrastent:: Balloon angioplasty versus elective sirolimus-eluting stenting (RIBS-II) trial [J].
Alfonso, Fernando ;
Perez-Vizcayno, Maria-Jose ;
Hernandez, Rosana ;
Bethencourt, Armando ;
Marti, Vicens ;
Lopez-Minguez, Jose R. ;
Angel, Juan ;
Mantilla, Ramon ;
Moris, Cesar ;
Cequier, Angel ;
Sabate, Manel ;
Escaned, Javier ;
Moreno, Raul ;
Bañuelos, Camino ;
Suarez, Alfonso ;
Macaya, Carlos .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (11) :2152-2160
[3]   Cell cycle progression - New therapeutic target for vascular proliferative disease [J].
Braun-Dullaeus, RC ;
Mann, MJ ;
Dzau, VJ .
CIRCULATION, 1998, 98 (01) :82-89
[4]   Understanding and managing in-stent restenosis: a review of clinical data, from pathogenesis to treatment [J].
Buccheri, Dario ;
Piraino, Davide ;
Andolina, Giuseppe ;
Cortese, Bernardo .
JOURNAL OF THORACIC DISEASE, 2016, 8 (10) :E1150-E1162
[5]   The clinical significance of CDK1 expression in oral squamous cell carcinoma [J].
Chen, Xin ;
Zhang, Feng-He ;
Chen, Qiao-Er ;
Wang, Yuan-Yin ;
Wang, Yin-Long ;
He, Jia-Cai ;
Zhou, Jian .
MEDICINA ORAL PATOLOGIA ORAL Y CIRUGIA BUCAL, 2015, 20 (01) :E7-E12
[6]   The microRNA miR-132 targets Lrrfip1 to block vascular smooth muscle cell proliferation and neointimal hyperplasia [J].
Choe, Nakwon ;
Kwon, Jin-Sook ;
Kim, Ju-Ryoung ;
Eom, Gwang Hyeon ;
Kim, Yongsook ;
Nam, Kwang-Il ;
Ahn, Youngkeun ;
Kee, Hae Jin ;
Kook, Hyun .
ATHEROSCLEROSIS, 2013, 229 (02) :348-355
[7]   Healing the injured vessel wall using microRNA-facilitated gene delivery [J].
Feinberg, Mark W. .
JOURNAL OF CLINICAL INVESTIGATION, 2014, 124 (09) :3694-3697
[8]   Pathological correlates of late drug-eluting stent thrombosis - Strut coverage as a marker of endothelialization [J].
Finn, Aloke V. ;
Joner, Michael ;
Nakazawa, Gaku ;
Kolodgie, Frank ;
Newell, John ;
John, Mike C. ;
Gold, Herman K. ;
Virmani, Renu .
CIRCULATION, 2007, 115 (18) :2435-2441
[9]   MicroRNAs for Restenosis and Thrombosis After Vascular Injury [J].
Gareri, Clarice ;
De Rosa, Salvatore ;
Indolfi, Ciro .
CIRCULATION RESEARCH, 2016, 118 (07) :1170-1184
[10]   Mir-22-3p Inhibits Arterial Smooth Muscle Cell Proliferation and Migration and Neointimal Hyperplasia by Targeting HMGB1 in Arteriosclerosis Obliterans [J].
Huang, Shui-chuan ;
Wang, Mian ;
Wu, Wei-bin ;
Wang, Rui ;
Cui, Jin ;
Li, Wen ;
Li, Zi-lun ;
Li, Wen ;
Wang, Shen-ming .
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2017, 42 (06) :2492-2506